| 1 |
35282632 | Site-specific DNA functionalization through the tetrazene-forming reaction in ionic liquids. | 2022 Feb 9 |
1 |
| 2 |
32526138 | Development of a Versatile and Modular Linker for Antibody-Drug Conjugates Based on Oligonucleotide Strand Pairing. | 2020 Jul 15 |
1 |
| 3 |
30991278 | An oligonucleotide probe incorporating the chromophore of green fluorescent protein is useful for the detection of HER-2 mRNA breast cancer marker. | 2019 Jul 1 |
3 |
| 4 |
31608694 | Silencing Breast Cancer Genes Using Morpholino Embedded DNA-Tile-AuNPs Nanostructures. | 2019 Dec |
1 |
| 5 |
29655990 | Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R. | 2018 Jun 10 |
1 |
| 6 |
29887936 | Rapid micro fluorescence in situ hybridization in tissue sections. | 2018 Jul |
1 |
| 7 |
27520726 | HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug. | 2017 Feb |
2 |
| 8 |
26930249 | Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. | 2016 Apr |
1 |
| 9 |
23395887 | Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. | 2013 Apr |
1 |
| 10 |
22454063 | Antisense-mediated exon skipping to shift alternative splicing to treat cancer. | 2012 |
3 |
| 11 |
19035464 | Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. | 2009 Feb 15 |
2 |
| 12 |
19228734 | Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. | 2009 Feb 15 |
1 |
| 13 |
19259095 | Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. | 2009 Mar 10 |
4 |
| 14 |
19317258 | Inhibitory effects of c-erbB-2 antisense oligonucleotide transfection on uterine endometrial cancer Ishikawa cell lines. | 2009 |
1 |
| 15 |
16166319 | Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. | 2005 Sep 15 |
1 |
| 16 |
14726684 | Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. | 2004 Feb |
2 |
| 17 |
15017081 | Selection of peptides for specific delivery of oligonucleotides into cancer cells. | 2004 |
1 |
| 18 |
15104891 | Rapid screening method for antisense oligonucleotides against human growth factor receptor p185(erbB-2). | 2004 Spring |
2 |
| 19 |
15570009 | Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. | 2004 Nov 15 |
1 |
| 20 |
23077754 | LTVSPWY peptide–modified PEGylated chitosan magnetic nanoparticles | 2004 |
4 |
| 21 |
12632082 | Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. | 2003 Apr |
1 |
| 22 |
14751825 | HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. | 2003 Dec |
3 |
| 23 |
12238811 | Direct measurement of the association constant of HER2/neu antisense oligonucleotide to its target RNA sequence using a molecular beacon. | 2002 Aug |
2 |
| 24 |
12435858 | Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. | 2002 Aug |
4 |
| 25 |
11399867 | Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. | 2001 Jul-Aug |
4 |
| 26 |
11687896 | Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. | 2001 Oct |
2 |
| 27 |
11726697 | Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif. | 2001 Dec 1 |
1 |
| 28 |
21340838 | c-erbB-2 Antisense Oligonucleotides Inhibit Serum-Induced Cell Spreading of Ovarian Cancer Cells. | 2001 |
1 |
| 29 |
10699953 | Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. | 2000 Mar 1 |
1 |
| 30 |
10938266 | Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. | 2000 Oct 27 |
1 |
| 31 |
11079160 | Ethanol enhances erbB-mediated migration of human breast cancer cells in culture. | 2000 Sep |
1 |
| 32 |
11156527 | HER2/neu antisense targeting of human breast carcinoma. | 2000 Dec 11 |
1 |
| 33 |
9888801 | Inhibition of transcription elongation in the HER-2/neu coding sequence by triplex-directed covalent modification of the template strand. | 1999 Jan 12 |
3 |
| 34 |
10487416 | Correlation between the activation of Neu tyrosine kinase and promotion of foci formation induced by selected organochlorine compounds in the MCF-7 model system. | 1999 |
2 |
| 35 |
9698539 | Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. | 1998 Jun |
8 |
| 36 |
9762367 | Detection of c-erbB-2 mRNAs using dig-labelled oligonucleotide probe with in situ hybridisation in human breast carcinoma: comparison with immunohistochemical results. | 1998 |
1 |
| 37 |
8564964 | Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide. | 1996 Feb 1 |
1 |
| 38 |
8721099 | [Basic studies on the 111In labeled antisense oligonucleotide for tumor imaging]. | 1996 Feb |
1 |
| 39 |
8783791 | Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides. | 1996 Spring |
4 |
| 40 |
8948649 | Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. | 1996 Nov 15 |
1 |
| 41 |
7909438 | Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. | 1994 Apr 15 |
3 |
| 42 |
7914192 | Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. | 1994 Aug 5 |
1 |
| 43 |
7947086 | erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. | 1994 Nov |
12 |
| 44 |
7901237 | Triplex formation inhibits HER-2/neu transcription in vitro. | 1993 Nov |
3 |
| 45 |
1348216 | Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis. | 1992 Apr 15 |
1 |
| 46 |
1749520 | Short biotinylated oligonucleotides bind non-specifically to senile plaques of Alzheimer's disease. | 1991 Sep 2 |
1 |